| Literature DB >> 34898424 |
Anna Carrera-Salinas1, Aida González-Díaz1,2, Laura Calatayud1,2, Julieta Mercado-Maza1, Carmen Puig1, Dàmaris Berbel1,2, Jordi Càmara1,2, Fe Tubau1,2, Imma Grau2,3, M Ángeles Domínguez1,4,5, Carmen Ardanuy1,2,5, Sara Martí1,2,6.
Abstract
This study provides an update on invasive Haemophilus influenzae disease in Bellvitge University Hospital (2014-2019), reporting its evolution from a previous period (2008-2013) and analysing the non-typeable H. influenzae (NTHi) population structure using a clade-related classification. Clinical data, antimicrobial susceptibility and serotyping were studied and compared with those of the previous period. Population structure was assessed by multilocus sequence typing (MLST), SNP-based phylogenetic analysis and clade-related classification. The incidence of invasive H. influenzae disease remained constant between the two periods (average 2.07 cases per 100 000 population), while the 30 day mortality rate decreased (20.7-14.7 %, respectively). Immunosuppressive therapy (40 %) and malignancy (36 %) were the most frequent comorbidities. Ampicillin and fluoroquinolone resistance rates had increased between the two periods (10-17.6 % and 0-4.4 %, respectively). NTHi was the main cause of invasive disease in both periods (84.3 and 85.3 %), followed by serotype f (12.9 and 8.8 %). NTHi displayed high genetic diversity. However, two clusters of 13 (n=20) and 5 sequence types (STs) (n=10) associated with clade V included NTHi strains of the most prevalent STs (ST3 and ST103), many of which showed increased frequency over time. Moreover, ST103 and ST160 from clade V were associated with β-lactam resistance. Invasive H. influenzae disease is uncommon, but can be severe, especially in the elderly with comorbidities. NTHi remains the main cause of invasive disease, with ST103 and ST160 (clade V) responsible for increasing β-lactam resistance over time.Entities:
Keywords: Haemophilus influenzae; epidemiology; invasive disease; structure population
Mesh:
Substances:
Year: 2021 PMID: 34898424 PMCID: PMC8767337 DOI: 10.1099/mgen.0.000723
Source DB: PubMed Journal: Microb Genom ISSN: 2057-5858
Demographic data, clinical characteristics and underlying conditions of patients with invasive disease
|
|
Overall study period (2008–2019) |
Comparison between periods | |||||
|---|---|---|---|---|---|---|---|
|
Young adults (<65 years) |
Elderly adults (≥65 years) |
|
First period (2008–2013) |
Second period (2014–2019) |
| ||
|
|
|
|
|
|
|
|
|
|
Age (mean± |
67.5±14.9; 21–96 |
51.6±11.4; 21–64 |
76.1±7.7; 65–96 |
|
64.3±16.1; 21–96 |
71.2±12.3; 37–93 |
|
|
Male sex |
88 (58.7) |
30 (56.6) |
58 (59.8) |
0.7311 |
52 (63.4) |
36 (52.9) |
0.2439 |
|
|
|
|
| ||||
|
Immunosuppressive therapy |
60 (40.0) |
22 (41.5) |
38 (39.2) |
0.86 |
28 (34.1) |
32 (47.1) |
0.13 |
|
Solid organ malignancy |
54 (36.0) |
17 (32.1) |
37 (38.1) |
0.48 |
26 (31.7) |
28 (41.2) |
0.24 |
|
Diabetes |
39 (26.0) |
8 (15.1) |
31 (32.0) |
|
18 (22.0) |
21 (30.9) |
0.26 |
|
Heart disease |
40 (26.7) |
7 (13.2) |
33 (34.0) |
|
15 (18.3) |
25 (36.8) |
|
|
COPD |
30 (20.0) |
4 (7.5) |
26 (26.8) |
|
18 (22.0) |
12 (17.6) |
0.54 |
|
Chronic liver disease |
18 (12.0) |
10 (18.9) |
8 (8.2) |
0.07 |
11 (13.4) |
7 (10.3) |
0.62 |
|
Hematologic malignancy* |
16 (10.7) |
7 (13.2) |
9 (9.3) |
0.58 |
9 (11.0) |
7 (10.3) |
1.00 |
|
Cerebrovascular disease |
7 (4.7) |
0 (0.0) |
7 (7.2) |
0.05 |
5 (6.1) |
2 (2.9) |
0.46 |
|
Organ transplant† |
10 (6.7) |
6 (11.3) |
4 (4.1) |
0.17 |
4 (4.9) |
6 (8.8) |
0.51 |
|
HIV |
3 (2.0) |
3 (5.7) |
0 (0.0) |
|
2 (2.4) |
1 (1.5) |
1.00 |
|
No underlying conditions |
27 (18.0) |
15 (28.3) |
12 (12.4) |
|
18 (22.0) |
9 (13.2) |
0.20 |
|
|
|
|
| ||||
|
Community acquired |
130 (86.7) |
43 (81.1) |
87 (89.7) |
0.21 |
71 (86.6) |
59 (86.8) |
1.00 |
|
Nosocomial |
20 (13.3) |
10 (18.9) |
10 (10.3) |
0.21 |
11 (13.4) |
9 (13.2) |
1.00 |
|
|
|
|
| ||||
|
Respiratory tract infection |
101 (67.3) |
27 (50.9) |
74 (76.3) |
|
49 (59.8) |
52 (76.5) |
|
|
Meningitis |
14 (9.3) |
5 (9.4) |
9 (9.3) |
1.00 |
9 (11.0) |
5 (7.4) |
0.58 |
|
Biliary tract infection |
14 (9.3) |
7 (13.2) |
7 (7.2) |
0.25 |
9 (11.0) |
5 (7.4) |
0.58 |
|
Primary bacteremia |
9 (6.0) |
6 (11.3) |
3 (3.1) |
0.07 |
7 (8.5) |
2 (2.9) |
0.18 |
|
Peritonitis |
3 (2.0) |
2 (3.8) |
1 (1.0) |
0.28 |
2 (2.4) |
1 (1.5) |
1.00 |
|
Other‡ |
9 (6.0) |
6 (11.3) |
3(3.1) |
0.07 |
6 (7.3) |
3 (4.4) |
0.51 |
|
|
4.8±2.5 |
3.4±3.0 |
5.5±1.8 |
|
4.3±2.4 |
5.3±2.5 |
|
|
|
27 (18.0) |
10 (18.9) |
17 (17.5) |
0.83 |
17 (20.7) |
10 (14.7) |
0.40 |
*Myeloma (n=8, 5.3%), leukaemia and lymphoma (n=4, 2.7 % each).
†Liver (n=4, 2.7%), bone marrow (n=3, 2.0%), kidney (n=2, 1.3%) and heart (n=1, 0.7%).
‡Epiglotittis, liver abscess (n=2, 1.3 % each), endometritis, facial cellulites, septic shock of an aortic valve prosthetic origin, surgical wound infection, and urinary tract infection (n=1, 0.7 % each).
Fig. 1.Frequencies of invasive infection by focus (2008–2019). (a) Focus of infection in the overall adult population. (b) Focus of infection in the young adult population (18–64 years). (c) Focus of infection in the elderly adult population (≥65 years). Infections caused by only one isolate were grouped as other: facial cellulitis, endometritis, urinary tract infection, and surgical wound infection (corresponding to young adults) and septic shock of an aortic valve prosthetic origin (corresponding to elderly adults).
Comparison of antimicrobial resistance rates of invasive during the two study periods
|
Antimicrobial compound |
MIC breakpoints (CLSI) |
First period* |
Second period |
| |||||
|---|---|---|---|---|---|---|---|---|---|
|
2008–2013 ( |
2014–2019 ( | ||||||||
|
S ≤ |
R ≥ |
MIC50 (mg l−1) |
MIC90 (mg l−1) |
%R |
MIC50 (mg l−1) |
MIC90 (mg l−1) |
%R | ||
|
Ampicillin |
1 |
4 |
0.25 |
2 |
10 |
0.25 |
>4 |
17.6 |
0.22 |
|
Amoxicillin/clavulanic acid† |
4 |
8 |
≤0.5 |
2 |
0 |
≤0.5 |
1 |
0 |
1 |
|
Cefuroxime |
4 |
16 |
1 |
2 |
0 |
≤0.5 |
1 |
1.5 |
0.49 |
|
Cefepime |
2 |
4 |
≤0.25 |
≤0.25 |
0 |
≤0.25 |
≤0.25 |
1.5 |
0.49 |
|
Cefotaxime |
2 |
4 |
≤0.06 |
≤0.06 |
0 |
≤0.06 |
≤0.06 |
0 |
1 |
|
Ceftriaxone |
2 |
4 |
≤0.12 |
≤0.12 |
0 |
≤0.12 |
≤0.12 |
0 |
1 |
|
Imipenem |
4 |
8 |
0.5 |
1 |
0 |
≤0.12 |
0.25 |
0 |
1 |
|
Chloramphenicol |
2 |
8 |
≤1 |
≤1 |
0 |
≤1 |
≤1 |
0 |
1 |
|
Tetracycline |
2 |
8 |
≤1 |
2 |
0 |
≤1 |
≤1 |
0 |
1 |
|
Ciprofloxacin |
1 |
2 |
≤0.03 |
≤0.03 |
0 |
≤0.03 |
≤0.03 |
4.4 |
0.12 |
|
Co-trimoxazole‡ |
0.5 |
4 |
≤0.5 |
>2 |
26 |
≤0.5 |
>2 |
27.9 |
0.85 |
|
Azithromycin |
4 |
8 |
1 |
2 |
1.4 |
2 |
4 |
0 |
0.49 |
*Only 70 of the 82 strains of the first period were viable.
†The ratio of amoxicillin/clavulanic acid was 2 : 1.
‡The ratio of co-trimoxazole was 1 : 19.
MIC, Minimum inhibitory concentration; R, resistant; %R, resistance rate; S, susceptible.
Mechanisms of β-lactam antimicrobial resistance among invasive strains (2014–2019). Amino acid substitutions in PBP3 and classification according to Dabernat et al. [25], and β-lactamase production
|
No. isolates |
MIC (mg l−1) |
Amino acid substitutions |
β-lactamase* | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
AMP |
AMC† |
Ile |
Asp |
Ala |
Met |
Ala |
Ile |
Gly |
Ala |
Asn |
Ala |
|
| ||
|
348 |
350 |
368 |
377 |
437 |
449 |
490 |
502 |
526 |
530 | ||||||
|
No changes |
32 |
≤0.12–0.25 |
≤0.5 |
|
|
− |
− | ||||||||
|
10 |
4 ->4 |
≤0.5–2 |
|
|
|
|
|
|
|
|
|
|
+ |
− | |
|
Group IIa |
1 |
0.5 |
1 |
|
|
|
|
|
|
|
|
Lys |
Ser |
− |
− |
|
1 |
1 |
1 |
|
Asn |
Glu |
Lys |
Ser |
− |
− | ||||||
|
1 |
1 |
1 |
|
Asn |
|
|
|
|
|
|
Lys |
|
− |
− | |
|
Group IIb |
1 |
1 |
1 |
|
|
|
|
|
|
Glu |
Val |
Lys |
|
− |
− |
|
2 |
0.5–1 |
1 |
|
Asn |
|
Ile |
|
|
|
Val |
Lys |
|
− |
− | |
|
Group IIc |
2 |
1 |
1 |
|
|
|
|
|
|
|
Thr |
Lys |
|
− |
− |
|
2 |
1 |
1 |
|
Asn |
|
|
|
|
|
Thr |
Lys |
|
− |
− | |
|
Group IId |
1 |
1 |
1 |
|
|
|
|
|
Val |
|
|
Lys |
|
− |
− |
|
Miscellaneous |
10 |
0.25–0.5 |
≤0.5–1 |
|
Asn |
|
− |
− | |||||||
|
1 |
≤0.12 |
≤0.5 |
Val |
|
− |
− | |||||||||
|
1 |
>4 |
2 |
|
Asn |
|
− |
+ | ||||||||
|
1 |
>4 |
≤0.5 |
|
Asn |
|
+ |
− | ||||||||
|
1 |
≤0.12 |
≤0.5 |
|
Asn |
Ser |
|
− |
− | |||||||
|
1 |
0.25 |
≤0.5 |
|
|
Thr |
|
|
|
|
|
|
|
− |
− | |
*β-lactamase production: positive (+), negative (−).
†The ratio of amoxicillin/clavulanic acid was 2 : 1.
AMC, amoxicillin/clavulanic acid; AMP, ampicillin; MIC, Minimum inhibitory concentration.
Fig. 2.Distribution of serotypes in invasive disease (2008–2019). (a) Frequencies of serotypes causing invasive disease per year. Frequencies are displayed at the upper part of each bar. (b) Distribution of serotypes causing invasive disease between 2008 and 2019. Donut charts, at the top of each bar, show the age group frequency; the frequency (%) in young adults is shown above. The number of isolates presenting each serotype is shown inside the donut charts.
Fig. 3.Core-SNP phylogenetic tree of invasive isolates (2014–2019). NTHi was classified into clades (I–VI) as defined by De Chiara et al. [12]. Relative bootstrap values other than one are given at branch nodes. Relative bootstrap values below 0.75 indicate that the branches are poorly supported. Strain Hi375 (CP009610) was used as the reference.
Fig. 4.Assembly-based core-SNP phylogenetic tree and clade distribution of nontypeable . The tree includes 213 NTHi genomes from three studies: De Chiara et al. [12], Pinto et al. [14] and Carrera-Salinas et al. (this study). Genomes were distributed in different clades (I–VI), as previously proposed according to the presence or absence of 17 accessory genes [12, 14]: HIFGL_RS05025: dinB (DNA polymerase IV); HIFGL_RS05250: ‘YbhB/YbcL family Raf kinase inhibitor-like protein’; HIFGL_RS07070: ‘ABC transporter substrate-binding protein’; HIB_RS06975: ‘7-carboxy-7-deazaguanine synthase QueE’; HIFGL_RS03555: ‘DEAD/DEAH box helicase family protein’; C645_RS00645: ‘Hypothetical protein’; C645_RS00650: ‘pirin family protein’; C645_RS00655: ‘DUF1016 family protein’; C645_RS08170: ‘Hypothetical protein’; HIFGL_RS07705: ‘nucleotidyltransferase domain-containing protein’; HIFGL_RS07710: ‘nucleotidyltransferase substrate-binding subunit’; HIB_RS07380: ‘ABC transporter ATP-binding protein’; HIFGL_RS06855: ‘5-oxoprolinase/urea amidolyase family protein’; R2846_RS08405: ‘TonB-dependent receptor’; NCTC8143_hmwA/B/C and F3031_hmwA/B/C: hmwA/B/C (high molecular weight protein A, B or C). The coloured dots show the most recent common ancestor (MRCA) found in each clade. Relative bootstrap values are given at branch nodes (values below 0.75 are poorly supported).